Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
Jeanne Tie, Joshua David Cohen, Kamel Lahouel et al. · New England Journal of Medicine · 2022
BACKGROUND: The role of adjuvant chemotherapy in stage II colon cancer continues to be debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor recurrence-free survival, whereas its absence predicts a low risk of recurrence. The benefit of adjuvant chemotherapy for ctDNA-positive patients is not well understood. METHODS: We conducted a trial to assess whether a ctDNA-guided approach could reduce the use of adjuvant chemotherapy without compromising recurrence risk. Patients with stage II colon cancer were randomly assigned in a 2:1 ratio to have treatment decisions guided by either ctDNA results or standard clinicopathological features. For ctDNA-guided management, a ctDNA-positive result at 4 or 7 weeks after surgery prompted oxaliplatin-based or fluoropyrimidine chemotherapy. Patients who were ctDNA-negative were not treated. The primary efficacy end point was recurrence-free survival at 2 years. A key secondary end point was adjuvant chemotherapy use. RESULTS: Of the 455 patients who underwent randomization, 302 were assigned to ctDNA-guided management and 153 to standard management. The median follow-up was 37 months. A lower percentage of patients in the ctDNA-guided group than in the standard-management group received adjuvant chemotherapy (15% vs. 28%; relative risk, 1.82; 95% confidence interval [CI], 1.25 to 2.65). In the evaluation of 2-year recurrence-free survival, ctDNA-guided management was noninferior to standard management (93.5% and 92.4%, respectively; absolute difference, 1.1 percentage points; 95% CI, -4.1 to 6.2 [noninferiority margin, -8.5 percentage points]). Three-year recurrence-free survival was 86.4% among ctDNA-positive patients who received adjuvant chemotherapy and 92.5% among ctDNA-negative patients who did not. CONCLUSIONS: A ctDNA-guided approach to the treatment of stage II colon cancer reduced adjuvant chemotherapy use without compromising recurrence-free survival. (Supported by the Australian National Health and Medical Research Council and others; DYNAMIC Australian New Zealand Clinical Trials Registry number, ACTRN12615000381583.).
Cited by 1,071 works. doi:10.1056/nejmoa2200075 Open-access PDF
Authors
- Jeanne Tie
- Joshua David Cohen
- Kamel Lahouel
- Serigne Lo
- Yuxuan Wang
- Suzanne Kosmider
- Rachel Wong
- Jeremy David Shapiro
- Margaret S. Lee
- Sam Harris
- Adnan Khattak
- Matthew Burge
- Marion Harris
- James F. Lynam
- Louise M. Nott
- Fiona Lee Day
- Theresa Hayes
- Sue‐Anne McLachlan
- Belinda Lee
- Janine Ptak
References
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support
- The National Comprehensive Cancer Network
- The REDCap consortium: Building an international community of software platform partners
- The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM
- Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma
- Circulating mutant DNA to assess tumor dynamics
- Detection and quantification of rare mutations with massively parallel sequencing
- Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
- International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study